United Therapeutics (NASDAQ:UTHR) EVP Sells $4,010,975.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $483.25, for a total value of $4,010,975.00. Following the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at $17,774,418.25. This trade represents a 18.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Up 1.3%

Shares of United Therapeutics stock opened at $485.36 on Friday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $519.99. The firm’s 50 day moving average is $486.75 and its two-hundred day moving average is $427.47. The firm has a market capitalization of $20.90 billion, a P/E ratio of 18.39, a P/E/G ratio of 2.58 and a beta of 0.85.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. HC Wainwright upped their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Royal Bank Of Canada increased their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. UBS Group lifted their target price on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Finally, Wells Fargo & Company increased their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $509.50.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in UTHR. AQR Capital Management LLC increased its position in United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after purchasing an additional 364,713 shares during the period. Invesco Ltd. grew its holdings in United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after acquiring an additional 419,588 shares during the period. Darwin Global Management Ltd. purchased a new position in United Therapeutics in the third quarter worth $317,617,000. Assetmark Inc. lifted its holdings in United Therapeutics by 38.1% in the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after acquiring an additional 197,384 shares during the period. Finally, Norges Bank acquired a new stake in United Therapeutics in the second quarter valued at $136,453,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.